Skip to main content

Table 1 Efficacy of a single oral dose of a novel chewable tablet (Simparica Trio™) containing sarolaner, moxidectin, and pyrantel pamoate against induced L4 larval and immature adult (L5) Ancylostoma caninum infections in dogs

From: Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

StudyIsolate originStage at time of treatmentDay of inoculationaDay of treatmentDay of worm recoveryTreatment groupbnNo. of infected dogsWorm count rangeGeometric mean worm countEfficacy compared to placebo
% EfficacyTest statistic
1EuropeL4 larvae− 707Placebo9911–3621.0
Simparica Trio™9000100t(7) = 21.62
P < 0.0001
2USAL4 larvae8Placebo884–179.2
Simparica Trio™810–20.198.4t(7) = 12.76
P < 0.0001
3USAImmature adults (L5)− 1107Placebo88110–260209.9
Simparica Trio™830–30.599.8t(7) = 22.77
P < 0.0001
4EuropeImmature adults (L5)Placebo8823–4129.6
Simparica Trio™8000100t(7) = 47.93
P < 0.0001
  1. aEach dog was inoculated with 200 ± 50 L3 A. caninum
  2. bSimparica Trio™ provided minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt)
  3. Abbreviation: n, number of animals per group